

Latest Update: Jun 24, 2022

Arthritis, rheumatoid

Category: Immune System|Musculoskeletal

Antibody Therapies: 112

Antibody Name 	Targets 	Organization 	Status 
priliximab	CD4	Centocor	Phase 1
PF-05230905	TNF α	Ablynx (Sanofi) Pfizer	Phase 2
rituximab	CD20	Biogen Genentech (Roche)	Approved
rituximab biosimilar, Dr. Reddy's Laboratories	CD20	Dr. Reddy's	Approved
rituximab biosimilar, PROBIOMED	CD20	Probiomed	Approved
rituximab biosimilar, Aryogen	CD20	Aryogen	Approved
rituximab biosimilar, Reliance Life sciences/ Torrent	CD20	Reliance Torrent Pharma	Approved
rituximab biosimilar, Sandoz (Novartis)	CD20	Sandoz (Novartis)	Approved
rituximab biosimilar, Celltrion	CD20	Celltrion Kern Pharma Mundipharma Teva	Approved
rituximab biosimilar, Henlius	CD20	Shanghai Henlius	Approved
rituximab biosimilar, Samsung BioLogics	CD20	Samsung Bioepis	Phase 3
rituximab biosimilar, Mabion SA	CD20	Mabion	Phase 3
rituximab biosimilar, Eden Biologics	CD20	Eden Biologics JHL Biotech	Phase 3
rituximab biosimilar, Archigen Biotech	CD20	Archigen Samsung Bioepis	Phase 3
rozibafusp alfa	BAFF ICOSLG	Amgen AstraZeneca	Phase 2
rituximab biosimilar, Lupin	CD20	Lupin	Phase 1
rituximab biosimilar, BioIntegrator	CD20	BioIntegrator	Phase 1



SSS-07	TNFα	3SBio Apexigen	Phase 2
SAN-300	VLA-1	Biogen Salix Pharmaceuticals Santarus	Phase 2
SM09	CD20	SinoMab	Preclinical
SM06	CD22	SinoMab	Preclinical
tocilizumab	IL-6R	Chugai Roche JW Pharmaceutical	Approved
tocilizumab biosimilar, Bio-Thera Solutions Ltd	IL-6R	Bio-Thera	Phase 3
tulinercept	TNFα	Protalix	Phase 2
telazorlimab	OX40	Glenmark Pharmaceuticals	Phase 2
theralizumab	CD28	TheraMAB	Phase 2
Tocilizumab biosimilar - Bio Thera Solutions	IL-6	Bio-Thera	Phase 3
Tocilizumab biosimilar - Qyuns Therapeutics	IL-6R	Qyuns	Phase 1
TNF2	TNFα	SinoMab	Preclinical
vobarilizumab	IL-6R	Ablynx (Sanofi)	Phase 2
xeligekimab	IL-17	Chongqing Genrix Bio	Phase 1

